MedTech develops robotic technology for more effective and less invasive

Montpellier-based start-up MedTech is a surgical robotic company that is broadening the use of medical technology to the benefit of both patients and practitioners alike. Listed on the Paris Euronext stock exchange, the success of the company’s developments have been recognised with a series of international industry awards.

Additional tools

Print  

" To the already strong support that MedTech receives from our existing shareholders has been added both individual and institutional investment. We thank them all for their trust as we continue the strong growth and development of our business. "

Bertin Nahum, Chief Executive Officer and Chairman, MedTech

More than 1 100 brain surgery interventions have been carried out already using one of MedTech’s developments known as the Rosa Brain robot. There are over 20 of these in use in the medical equipment of centres across Europe, North America, Saudi Arabia, China and Russia. The technology has been used successfully with patients suffering from a variety of diseases including Parkinson’s, hydrocephalus and drug-resistant forms of epilepsy. Using laser-guided robotic arms, Rosa Brain makes interventions more efficient and less invasive.

In 2013, MedTech received the Frost & Sullivan European Surgical Robotics Company of the Year for Neurosurgical Inventions Award. The company sees a greater part of its success being due to a commitment to continuous innovation. Extending its product range, in addition to Rosa Brain, MedTech has used R&D funds to develop Rosa Spine. The market potential for these two Rosa products is estimated at EUR 2.5 billion.

Medical innovation leads to economic success

MedTech was established in 2002 and is backed by four venture capital investment funds, including the initiative for Joint European Resources for Micro to Medium Enterprises (JEREMIE). In 2013, the company launched a successful Initial Public Offering (IPO), raising EUR 20 000 000 on the New York Stock Exchange (NYSE) Euronext in Paris. Those funds have helped the French-based company set itself on course to double its commitments in terms of research and development (R&D) in a world market for robotic surgery equipment that is growing rapidly. It is the first time that a small to medium enterprise (SME), supported through JEREMIE with money from the European Regional Development Fund (ERDF) has gone on to success with an IPO.

Thanks to a market capitalisation of EUR 64 500 000 and a turnover in 2012 – 2013 of EUR 1 800 000, MedTech is aiming at EUR 20 000 000 of sales in 2016.

Total investment and EU funding

Total investment for the project “MedTech” is EUR 24 000 000. The EU’s European Regional Development Fund (ERDF) is contributing EUR 180 000 through JEREMIE for the 2007-2013 programming period.

Draft date

30/09/2014

Videos